Allogene Therapeutics
Ben Beneski has extensive work experience in the biotechnology and pharmaceutical industry. Ben is currently serving as the Vice President of Manufacturing at Allogene Therapeutics since February 2022. Prior to this role, they held the position of Executive Director and Plant Manager at the same company from June 2019 to February 2022.
Before joining Allogene Therapeutics, Ben worked at Vir Biotechnology, Inc. as the Sr. Director of CMC Lifecycle Operations from May 2018 to May 2019.
Ben also has a long history at Amgen, where they held various positions including Director of Global Operations from November 2013 to May 2018, Director of Manufacturing from June 2012 to November 2013, Sr. Manager of Manufacturing from May 2006 to June 2012, and Process Engineer from September 2003 to May 2006.
Their early engineering experience in the industry began at Abbott Bioresearch Center, where they worked as an Engineer from 1999 to 2003.
Ben Beneski earned a Bachelor of Engineering degree in Chemical Engineering from Stevens Institute of Technology from 1994 to 1998. Ben then pursued a High Tech MBA from the D'Amore-McKim School of Business at Northeastern University from 2001 to 2003.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.